| |
| |
| |
| |
| |
| Dr
PRABHAT RANJAN MISHRA |
|
| |
 |
|
Principal Scientist
Pharmceutics Division
Central Drug Research Institute
Lucknow 226031 |
| |
| |
|
RESEARCH EXPERIENCE |
• |
Research Experience: As a scientist 'C' in Central Drug Research Institute
and Present position in Pharmaceutics Division since 04.09.2003 to 03.09.2007 to till date. |
• |
As a scientist 'E-I' in CSIR-Central Drug Research Institute and Present position in Pharmaceutics Division since 04.09.2007 to till date. |
• |
Worked as a visiting scientist at Institute of Pharmacy and Pharmaceutical technology, Freie Universität Berlin, Germany from July 2008 to September 2008 under INSA–DFG Bilateral Exchange Programme. |
• |
Teaching/research Experience: Three years (Hamdard University, New-Delhi) |
| • |
Industrial Experience: Worked as production Executive in Nicholas Piramal India Ltd. From 26.10.1995 to 30.04.1997. |
|
| |
| CURRENT
AREAS OF RESEARCH |
| • |
The current area of interest in our lab is to explore nanomaterial based targeted delivery to tissue of interest especially for infectious diseases and endocrine disorders. Our lab is involved in development of layer-by-layer technology, Nanocrystal Technology, Solid lipid nanoparticles and Ligand/receptor based targeting.
The delivery system are also being explored that could in principle interact with Lipopolysaccharide and prevent subsequent lethal cascading event. As sepsis is a spectrum of clinical conditions caused by the immune response of a patient to infection that is characterized by systemic inflammation and coagulation.
It includes the full range of response from systemic inflammatory response to organ dysfunction to multiple organ failure and ultimately death. Compounds that bind to components of the gram-negative outer membrane [i.e Lipopolysaccharide (LPS)] and ablate their ability to activate surface receptors would be good candidates as an antiendotoxic agent. However, to develop a molecule that could bind specifically to LPS is tedious job. Few polycationic substances are known to bind with lipid A portion of LPS by simple hydrophobic and electrostatic interaction but are reported to be severely toxic and cannot be administered repeatedly.
The strategy is to develop target oriented delivery systems with certain degree of cationicity and hydrophobicity that could interact with LPS (either hydrophobic or electrostatic) to alleviate macrophage stimulation and circumvent further toxic cascading events.
Based on layer-by-layer technology we have developed nanocapsules for enhanced delivery of flavanoids for the conditions of osteoporosis. Interestingly, when given orally, the auto-digestion of core particles in GI milieu transform these microcapsules in to nano-walled matrix that facilitates penetration of flavanoid into lymphatic route through Peyer’s patches and lacteals and thus showing enhanced levels of flavanoid in serum and bone marrow.
Self assembling technique through layer-by-layer technology
Scanning Electron Microscopy of (A) porous CaCO3 particles. B: Fabricated layer-by-layer based capsules (C) Transmission Electron microscopy of layer-by-layer based capsules (D) layer-by-layer based capsules after incubation in gastric fluid.
Confocal microscopic images through transverse section of ileum of intestine following oral administration of FITC tagged LBL-matrix showing absorption of LBL matrix through lacteals of villi and in Peyer’s patches.
Schematic representation of the formation of Phosphatidylserine (PS) specific ligand anchored nanocapsules (NCs). (A) Adsorption of charged phospholipid (anionic PS) on oppositely charged NCs (PRM layer) due to electrostatic attraction (B) Spreading of PS on NCs. can provide new insight for efficient drug delivery to specialized macrophages and thus may be designed for effective use for macrophage-specific delivery systems especially for leishmaniasis. The system was found to provide new insight for specific delivery to specialized macrophages especially for leishmaniasis.
3D representation of nanocrystals through AFM. Nanocrystal technology involves production of stable nanocrystals from high pressure homogenization (Top down technique) is a field of interest for delivery of hydrophobic molecules with improved bioavailability.
|
|
| |
| RESEARCH
GROUP |
• |
Prashant Shukla (SRF-CSIR) |
|
• |
Ashwini Kumar (SRF-ICMR) |
• |
Rahul Shukla (SRF-CSIR) |
• |
Pramod Gupta (SRF-CSIR) |
• |
Pankaj Dwivedi (SRF-ICMR) |
• |
Shweta Sharma (JRF-CSIR) |
| • |
Priyanka Tripathi (SRF-CSIR)
|
|
| |
| CAREER HIGHLIGHTS |
• |
Recipient of Director’s special incentive award for excellence in research in 2013. |
• |
Best paper award at International Conference on Safe Use of Nanomaterials (SUN 2011) held at Taj Hotel organized by IITR, Lucknow, India during February 1-3, 2011. |
• |
Awarded INSA-DFG fellowship under Bilateral Exchange Programme to carry out research at Free university, Berlin Germany in 2008. |
• |
Best paper award at 1st International Conference on Nanomaterial Toxicology held at IITR, Lucknow, India during February 2008. |
• |
Young scientist (Fast Track) by Department of Science and Technology, India (2006). |
• |
Member, Editorial Board of Journal “Recent Patents in drug delivery and Formulations (Bentham sciences). |
• |
Member of Technical committee (BIS) Medical biotechnology and nano-technology, Govt. of India. |
• |
Founder Member Indian Nanoscience Society |
|
| FACILITIES AVAILABLE |
• |
Atomic Force Microscope, High Pressure Homogenizer, Zetasizer, Ultracentrifuge
High Pressure Liquid Chromatograph, Probe sonicator, Lipid extruder, High Speed homogenizer, Freeze dryer, Deep Freezer etc. |
|
| SELECTED
PUBLICATIONS |
• |
Khedgikar V, Kushwaha P, Gautam J, Verma A Changkija B, Kumar A, Sharma S, Nagar GK, Singh D, Trivedi PK, Sangwan N S, Mishra PR, Trivedi R. Withaferin A: a proteasomal inhibitor promotes healing after injury and exerts bone anabolic effect. Cell Death and Dis. (2013). (In press)(I F 6.044) |
• |
Girish K Gupta, Avinash Kumar, Vikram Khedgikar, Priyanka Kushwaha, Jyoti Gautam, Geet K Nagar, Varsha Gupta, Ashwini Verma, Anil Kumar Dwivedi, Amit Misra, Ritu Trivedi and Prabhat Ranjan Mishra Enhancement of osteogenic efficacy of kaempferol through engineered layer-by-layer matrix: A study in ovariectomized rats. Nanomedicine 8(5) 757-771(2013). (IF 5.33) |
• |
Monika Sharma, Ritu Malik, Ashwni Verma, Pankaj Dwivedi, Gabbar Singh Banoth, Nagendra Pandey, Jayant Sarkar, Prabhat Ranjan Mishra, and Anil Kumar Dwivedi Folic Acid Conjugated Guar Gum Nanoparticles for Targeting Methotrexate to Colon Cancer J. Biomed. Nanotechnol. 9, 96-106 (2013). (IF 5.26) |
• |
Vikas Jain, Nitin K. Swarnakar, Prabhat R. Mishra, Ashwni Verma, Ankur Kaul, Anil K. Mishra, Narendra K. Jain Paclitaxel loaded PEGylated gleceryl monooleate based nanoparticulate carriers in chemotherapy Biomaterials 33(29): 7206-20 (2012). (I.F. 7.404) |
• |
Shaswat Kansal, Rati Tandon, Pankaj Dwivedi, Pragya Misra, P.R.P Verma, Anuradha Dube and Prabhat Ranjan Mishra Development of oil templated nanocapsules bearing doxorubicin for macrophage targeting through Phosphatidylserine ligand: A system for intervention in Visceral Leishmaniasis J. Antimicrob. Chemother. 67 (11), 2650-2660 (2012). (I.F. 5.34) |
• |
Avinash Kumar, Girish K Gupta , Vikram Khedgikar, Jyoti Gautam, Priyanka Kushwaha, Bendangla Changkija, Geet K Nagar, Varsha Gupta, Ashwni Verma, Anil Kumar Dwivedi, Naibedya Chattopadhyay , Prabhat R Mishra, Ritu Trivedi. In-vivo efficacy studies of layer-by-layer nano-matrix bearing kaempferol for the conditions of osteoporosis: A study in ovariectomized rat model. Eur. J. Pharm. Biopharm. 82 (2012) 508-517. (I.F. 4.268) |
• |
Pankaj Dwivedi, Shaswat Kansal, Monika Sharma, Rahul Shukla, Ashwini Verma, Prashant Shukla, Priyanka Tripathi, Pramod Gupta, Deepika Saini, Kiran Khandelwal, Rahul Verma, Anil Kumar Dwivedi and Prabhat Ranjan Mishra Exploiting 4-sulphate N-acetyl galactosamine decorated gelatin nanoparticles for effective targeting to professional phagocytes in vitro and in vivo. J. Drug Targeting 20, (10) 883–896 (2012). (I.F. 2.96) |
• |
Deepak Singodia, Prashant Khare, Anuradha Dube, Kalyan Mitra and Prabhat Ranjan Mishra Investigations on Feasibility of in-situ Development of Amphotericin B Liposomes for Industrial Applications, J Liposome Res. 22 (1) 8-17, 2012. (IF 2.091) |
• |
D. Singodia, A. Verma, R.K. Verma, P. R. Mishra Investigations on Alternate Approach to Target Mannose Receptors on Macrophages using 4-Sulfated N-Acetyl Galactosamine more Efficiently as Compared to Mannose Decorated Liposomes : An Application in Drug Delivery, Nanomedicine, Nanotechnology, Biology and Medicine 8 (4) 468-477 (2012). (I.F. 6.69) |
• |
P.R Mishra An Investigation on the approach to target Lipopolysaccharide through Polymeric capped Nano-structured formulation for the management of sepsis. J. Biomed. Nanotechnol. 7(1), 47-49 (2011). (IF 5.26) |
• |
D. Singodia, S.Talegaonkar, R.K.Khar and P.R. Mishra Novel Polymer Coupled Lipid Nanoparticle of Paclitaxel with Synergistic Enhanced Efficacy against Cancer. J. Biomed. Nanotechnol. 7(1), 125-126, (2011). (IF 5.26) |
• |
D. Singodia, P. Khare, A. Dube, S.Talegaonkar, R.K.Khar and P.R. Mishra. Development and Performance Evaluation of Alginate-Capped Amphotericin B Lipid Nano-constructs against Visceral Leishmaniasis. J Biomed Nanotechnol. 7(1), 123-124, 2011. (IF 5.26) |
• |
V. Jain, D. Garg, G. Gupta, R. Pal, G.B. Shiva Kinshasa, P.K. Shukla and P.R. Mishra: Surfactant based ion pair complexes for improved retention in Submicron Emulsion: A study with Ciprofloxacin Int. J. Pharm. 409, 237–244 (2011). (IF 3.62) |
• |
D.Singodia, G.K.Gupta, A.Verma, V.Singh, P.Shukla, P.Misra, S.Sundar, A. Dube and P.R. Mishra. Development and Performance Evaluation of Amphotericin B Transfersomes against Resistant and Sensitive Clinical Isolates of Visceral Leishmaniasis. J. Biomed. Nanotechnol. 6, 293-302 (2010). (IF 5.26) |
• |
P. Shukla, G. K.Gupta, D. Singodia, R. Shukla, A. Verma, P. Dwivedi, S. Kansal and P. R. Mishra Emerging trend in Nano-engineered Polyelectrolyte based Surrogate carriers for Delivery of Bioactives. Expert Opin. Drug Deliv. 7(9):993-1011 (2010). (IF 4.87) |
• |
Trivedi R, Kumar A, Gupta V, Gupta GK, Mishra PR, Dwivedi AK and Chattopadhyay N Polymeric Biodegradable Nano-Matrix-Associated Oral Delivery of Small Molecule To Enhance Osteogenic Effect: A Case Of Kaempferol Osteoporosis International 21 ( suppl 1), 378-378 (2010). (IF 4.997) |
| • |
S.S. Bisht, N. Dwivedi, V. Chaturvedi, N. Anand, M. Misra, R. Sharma, B. Kumar, R. Dwivedi, S. Singh, S. Sinha, V. Gupta, P.R. Mishra, A.K. Dwivedi, R.P. Tripathi. Synthesis and optimization of antitubercular activities in a series of 4-(aryloxy) phenyl cyclopropyl methanols, Eur. J. Med. Chem. 45, 5965-5978 (2010). (IF 3.35) |
• |
Vikas Jain, B Nath, MA Siddiqui, PP Shah, A.B Pant and P.R. Mishra. galactosylated chylomicron mimicking emulsion for specific delivery of encapsulated taxol: an in vitro study J. Pharm. Pharmacol (2009) 61, 303-310. (I.F 2.03) |
• |
Prabhat R. Mishra, Loaye Al Shaal, Rainer H. Müller, Cornelia M. Keck Production and characterization of Hesperetin nanosuspensions for dermal delivery. Int. J. Pharm (2009) 371, 182–189. (IF 3.62) |
| BOOK
CHAPTERS |
• |
Hydrogels based controlled delivery of therapeutic agents. In: Progress in Controlled and Novel Drug Delivery Systems. (Ed. N.K.Jain) Ist edition 341-360 (2004). |
• |
Biotinylated erythrocytes for specific delivery of drugs. In: Progress in Controlled and Novel Drug Delivery Systems. (Ed. N.K.Jain) Ist edition 248-258 (2004). |
• |
Provesicles as surrogate carrier for improved drug delivery. In: Progress in Controlled and Novel Drug Delivery Systems. (Ed. N.K.Jain) Ist edition 259-274 (2004). |
• |
Good Manufacturing and laboratory practices In: Pharmaceutical product Development. (Ed. N.K. Jain) Ist edition 468-502 (2005). |
• |
Pharmaceutical Validation In; Pharmaceutical product Development (Ed. N.K. Jain) Ist edition 503-528 (2005). |
| PATENTS |
• |
PR Mishra, Ritu Trivedi, GK Gupta, A Kumar, V Gupta, SK Rath, K Srivastava, N Chattopadhyay Controlled Release Micro-Capsule for osteogenic action EP Patent 2, 400,957 (2012). |
• |
PR Mishra, Ritu Trivedi, GK Gupta, A Kumar, V Gupta, SK Rath, K Srivastava, N Chattopadhyay Controlled Release Micro-Capsule for osteogenic action US Patent 13/203,603 (2010). |
• |
PR Mishra, Ritu Trivedi, GK Gupta, A Kumar, V Gupta, SK Rath, K Srivastava, N Chattopadhyay Controlled Release Micro-Capsule for osteogenic action Australia Patent 2010217238 (2010) |
• |
PR Mishra, Ritu Trivedi, GK Gupta, A Kumar, V Gupta, SK Rath, K Srivastava, N Chattopadhyay Controlled Release Micro-Capsule for osteogenic action Canada Patent 2753993 (2010) |
• |
Patent Application No. 0842 DEL 2006 “Composition and methods of nonionic surfactant based vesicular formulation for improved delivery of cyclosporine”. |
|
|
|
| |
|